Table 3.
Attitudes towards transparency
| N | Strongly disagree | Disagree | Neutral | Agree | Strongly agree | |
| Payments by pharmaceutical companies are a risk for the independence of clinical practice and research | 233 | 26/233 (11%) | 41/233 (18%) | 35/233 (15%) | 90/233 (39%) | 41/233 (18%) |
| In principle, I approve of transparency | 233 | 4/233 (2%) | 3/233 (1%) | 16/233 (7%) | 39/233 (17%) | 171/233 (73%) |
| Collaboration with pharmaceutical companies and receiving payments by those companies is part of the medical profession | 230 | 19/230 (8%) | 35/230 (15%) | 66/230 (28%) | 71/230 (31%) | 39/230 (17%) |
| Disclosure of payments should be more nuanced | 233 | 8/233 (3%) | 7/233 (3%) | 43/233 (18%) | 51/233 (22%) | 124/233 (53%) |
| Disclosure of payments increases patients' trust in me | 233 | 72/233 (31%) | 45/233 (19%) | 75/233 (32%) | 32/233 (14%) | 9/233 (4%) |
| Disclosure leads to a wrong impression in the public | 233 | 9/233 (4%) | 24/233 (10%) | 31/233 (13%) | 78/233 (33%) | 91/233 (39%) |
| In case you are working in research | ||||||
| Transparency guidelines impede my scientific work | 154 | 45/154 (29%) | 40/154 (26%) | 29/154 (19%) | 32/154 (21%) | 8/154 (5%) |
| I have been confronted with disclosures within the context of a published study at least once | 154 | 56/154 (36%) | 17/154 (11%) | 22/154 (14%) | 24/154 (16%) | 35/154 (23%) |
| My research results were criticised because of my disclosures at least once | 152 | 119/152 (78%) | 11/152 (7%) | 13/152 (9%) | 5/152 (3%) | 4/152 (3%) |
| The undifferentiated displaying of the disclosures brings science into disrepute | 155 | 10/155 (6%) | 5/155 (3%) | 16/155 (10%) | 37/155 (24%) | 87/155 (56%) |